[Experience with and outlook for the use of cisplatin in the combined therapy of osteogenic sarcoma].
The effectiveness of cis-diammine-dichloroplatinum (cisplatinum, platidiam, DDP) alone or as a component of combined treatment was evaluated in 85 patients with osteogenic sarcoma. The said drugs were used as adjuvants following radical surgery (group I-18 cases), in combined treatment of solitary and single lung metastases (group 2-7 cases) and in 60 patients with advanced tumors (group 3). An analysis of long-term results showed response in 30.8% in group 3. In group 2, application of chemotherapy plus surgery was followed by remissions of 2-46+-month duration (mean-13.9 months). In group I, 78.7% are expected to survive metastasis-free more than 12 months. Toxicity was moderate, with nausea and vomiting (87.1%), myelosuppression (52.8%), nephrotoxicity (48.6%) and alopecia (75.7%) being the most common side-effects.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000401:mortality / Q000628:therapy*; D002360:Carubicin / Q000008:administration & dosage; D002648:Child; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy; D008297:Male; D012516:Osteosarcoma / Q000401:mortality / Q000628:therapy*; D011182:Postoperative Care; D012074:Remission Induction; D013997:Time Factors
D004317:Doxorubicin; D003520:Cyclophosphamide; D002360:Carubicin; D002945:Cisplatin
Opy primeneniia i perspektivy ispol'zovaniia tsis-platina v kombinirovannoĭ terapii osteogennoĭ sarkomy.